AstraZeneca’s anifrolumab has failed to meet the primary objective in a late-stage clinical trial in moderate-to-severe systemic lupus erythematosus (SLE). ... control. The result of this trial is disappointing for patients and the lupus community.”

The drug has potential in a variety of autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis, says Celgene, which also claims rights to related second-generation candidates.

Meanwhile, Merck suffered a setback in its mid-stage pipeline recently after its systemic lupus erythematosus (SLE) candidate atacicept failed to meet its objectives in a clinical trial, although it did

In a similar vein, Biogen Idec has sold its royalty rights to Benlysta (belimunab) for the treatment of systemic lupus erythematosus, to DRI Capital Managed Fund. ... Royalty monetisation. Benlysta (belimunab) for the treatment of systemic lupus